Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib

Dermatologic Therapy

Volumn 24, Issue 4, 2011, Pages 386-395

  Amitay Laish, Iris ^a   Stemmer, Salomon M ^a,b   Lacouture, Mario E ^c  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

cutaneous; dasatinib; imatinib mesylate; nilotinib; side effects; tyrosine kinase inhibitors

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CORTICOSTEROID; DASATINIB; DIURETIC AGENT; IMATINIB; NILOTINIB; PHENYLEPHRINE; PREDNISOLONE; PREDNISONE; STEROID;

ACNE; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ADVERSE DRUG REACTION; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BULLOUS SKIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CHEILITIS; CHRONIC MYELOID LEUKEMIA; CONGESTIVE HEART FAILURE; CORTICOSTEROID THERAPY; DERMATITIS; DIURETIC THERAPY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG POTENCY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DRY SKIN; EPITHELIUM TUMOR; ERYTHEMA NODOSUM; ERYTHRODERMA; EYELID EDEMA; GASTROINTESTINAL STROMAL TUMOR; GRAFT VERSUS HOST REACTION; HAND FOOT SYNDROME; HIDRADENITIS; HUMAN; HYPERHIDROSIS; HYPERPIGMENTATION; HYPOPIGMENTATION; LICHENOID ERUPTION; LYMPHOPROLIFERATIVE DISEASE; MACULOPAPULAR RASH; MOLECULAR PATHOLOGY; MUCINOSIS; MUCOSA INFLAMMATION; MYCOSIS FUNGOIDES; NAIL DISEASE; NAIL DYSTROPHY; NONHUMAN; PANNICULITIS; PERIORBITAL EDEMA; PHOTOSENSITIVITY; PIGMENTATION; PITYRIASIS ROSEA; PLEURA EFFUSION; PORPHYRIA CUTANEA TARDA; PRURITUS; PSORIASIS; SIDE EFFECT; SKIN EDEMA; SKIN MANIFESTATION; SKIN NODULE; SKIN ULCER; STEVENS JOHNSON SYNDROME; SYRINGOMA; SYSTEMATIC REVIEW; URTICARIA; VASCULITIS; XEROSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; HUMANS; NEOPLASMS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES;

EID: 80052719361     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2011.01431.x     Document Type: Article

References (77)

1. Guilhot F,. Indications for imatinib mesylate therapy and clinical management. Oncologist 2004: 9: 271-281. (Pubitemid 38756876)
2. Heidary N, Naik H, Burgin S,. Chemotherapeutic agents and the skin: an update. J Am Acad Dermatol 2008: 58: 545-570. (Pubitemid 351375051)
3. van Daele PL, Dik WA, Thio HB, et al,. Is imatinib mesylate a promising drug in systemic sclerosis? Arthritis Rheum 2008: 58: 2549-2552.
4. Sabnani I, Zucker MJ, Rosenstein ED, et al,. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology (Oxford) 2009: 48: 49-52.
5. Kay J, High WA,. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 2008: 58: 2543-2548.
6. O'Hare T, Walters DK, Stoffregen EP, et al,. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005: 65: 4500-4505. (Pubitemid 40740783)
7. Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL,. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci U S A 2005: 102: 3395-3400. (Pubitemid 40328056)
8. Piccaluga PP, Paolini S, Martinelli G,. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Cancer 2007: 110: 1178-1186. (Pubitemid 47435586)
9. Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD,. (AMN107) Nnilotinib: a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006: 94: 1765-1769. (Pubitemid 43882564)
10. Deininger MWN, O'Brien SG, Ford JM, Druker BJ,. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003: 21: 1637-1647. (Pubitemid 46594119)
11. Basso FG, Boer CC, Correa ME, et al,. Skin and oral lesions associated to imatinib mesylate therapy. Support Care Cancer 2009: 17: 465-468.
12. Valeyrie L, Bastuji-Garin S, Revuz J, et al,. Adverse cutaneous reactions to imatinib (STI-571) in Philadelphia chromosome positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003: 48: 201-206. (Pubitemid 36232317)
13. Brouard M, Saurat JH,. Cutaneous reactions to STI571. N Engl J Med 2001: 345: 618-619.
14. Scheinfeld N,. Imatinib mesylate and dermatology, part 2: a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol 2006: 5: 228-231.
15. Kantarjian H, Sawyers C, Hochhaus A, et al,. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002: 346: 645-652. (Pubitemid 34815868)
16. Arora B, Kumar L, Sharma A, Wadhwa J, Kochupillai JWV,. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate. Ann Oncol 2004: 15: 358-359. (Pubitemid 38262643)
17. Kuwano Y, Asahina A, Watanabe R, Fujimoto M, Ihn H, Tamaki K,. Heliotrope-like eruption mimicking dermatomyositis in a patient treated with imatinib mesylate for chronic myeloid leukemia. Int J Dermatol 2006: 45: 1249-1251. (Pubitemid 44560387)
18. Hensley ML, Ford JM,. Imatinib treatment specific issues: related to safety, fertility and pregnancy. Semin Hematol 2003: 40: 21-25.
19. Heuchel R, Berg A, Tallquist M, et al,. Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3â kinase signaling. Proc Natl Acad Sci U S A 1999: 96: 11410-11415. (Pubitemid 29487394)
20. Legros L, Cassuto JP, Ortonne JP,. Imatinib mesilate (Glivec): a systemic depigmenting agent for extensive vitiligo? Br J Dermatol 2005: 153: 691-692. (Pubitemid 41248249)
21. Campbell T, Felsten L, Moore J,. Disappearance of lentigines in a patient receiving imatinib treatment for familial gastrointestinal stromal tumor syndrome. Arch Dermatol 2009: 145: 1313-1316.
22. Huang X, Patel S, Ahmed N, Seiter K, Liu D,. Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors. Drug Des Devel Ther 2009: 6: 215-219.
23. Mcpherson T, Sherman V, Turner R,. Imatinib-associated hyperpigmentation, a side effect that should be recognized. J Eur Acad Dermatol Venereol 2009: 23: 82-83.
24. Etienne G, Cony-Makhoul P, Mahon FX,. Imatinib mesylate and grey hair. N Engl J Med 2000: 347: 446.
25. Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M,. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2003: 98: 2483-2487. (Pubitemid 37466664)
26. Dippel E, Haas N, Grabbe J, Schadendorf D, Hamann K, Czarnetzki BM,. Expression of the c-kit receptor in hypomelanosis: a comparative study between piebaldism, nevus depigmentosus and vitiligo. Br J Dermatol 1995: 132: 182-189.
27. Cario-Andre M, Ardilouze L, Pain C, Gauthier Y, Mahon FX, Taieb A,. Imatinib mesilate inhibits melanogenesis in vitro. Br J Dermatol 2006: 155: 493-494. (Pubitemid 44050600)
28. Kuraishi N, Nagai Y, Hasegawa M, Ishikawa O,. Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature. Acta Derm Venereol 2010: 90: 73-76.
29. Kawakami T, Kawanabe T, Soma Y,. Cutaneous lichenoid eruption caused by imatinib mesylate in a Japanese patient with chronic myeloid leukaemia. Acta Derm Venereol 2009: 89: 325-326.
30. Dalmau J, Peramiquel L, Puig L, Fernandez-Figueras MT, Roe E, Alomar A,. Imatinib-associated lichenoid eruption: acitretin treatment allows maintained antineoplastic effect. Br J Dermatol 2006: 154: 1213-1216. (Pubitemid 43727416)
31. Dickens E, Lewis F, Bienz N,. Imatinib: a designer drug, another cutaneous complication. Clin Exp Dermatol 2009: 34: 603-604.
32. Deguchi N, Kawamura T, Shimizu A, et al,. Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukemia. Br J Dermatol 2006: 154: 1216-1218. (Pubitemid 43727417)
33. Miyagawa S, Fujimoto H, Ko S, Hirota S, Kitamura Y,. Improvement of psoriasis during imatinib therapy in a patient with a metastatic tumour. Br J Dermatol 2002: 147: 406-407.
34. Konstantopoulos K, Papadogianni A, Dimopoulou M, Kourelis C, Meletis J,. Pityriasis rosea associated with imatinib (STI571, Gleevec). Dermatology 2002: 205: 172-173.
35. Brazzelli V, Prestinari F, Roveda E, et al,. Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases. J Am Acad Dermatol 2005: 53: S240-S243. (Pubitemid 41443480)
36. Brouard MC, Prins C, Mach-Pascual S, Saurat JH,. Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia. Dermatology 2001: 203: 57-59. (Pubitemid 32830533)
37. Schwarz M, Kreuzer KA, Baskaynak G, Dorken B, le Coutre P,. Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia. Eur J Haematol 2002: 69: 254-256. (Pubitemid 35448131)
38. Gambillara E, Laffitte E, Widmer N,. Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia. Dermatology 2005: 211: 363-365. (Pubitemid 41642114)
39. Hsiao LT, Chung HM, Lin JT, et al,. Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol 2002: 117: 620-622.
40. Rule SA, O'Brien SG, Crossman LC,. Managing cutaneous reactions to imatinib therapy. Blood 2002: 100: 3434-3435. (Pubitemid 35217102)
41. Severino G, Chillotti C, De Lisa R, Del Zompo M, Ardau R,. Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. Ann Pharmacother 2005: 39: 162-164. (Pubitemid 40052395)
42. Vidal D, Puig L, Sureda A, Alomar A,. Sti571-induced Stevense Johnson syndrome. Br J Haematol 2002: 119: 274-275.
43. Pavithran K, Thomas M,. Imatinib induced Stevens-Johnson syndrome: lack of recurrence following re-challenge with a lower dose. Indian J Dermatol Venereol Leprol 2005: 71: 288-289. (Pubitemid 41191373)
44. Sanchez-Gonzalez B, Pascual-Ramirez JC, Fernandez-Abellan P, Belinchon-Romero I, Rivas C, Vegara-Aguilera G,. Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia. Blood 2003: 101: 2446. (Pubitemid 36302095)
45. Mahapatra M, Mishra P, Kumar R,. Imatinib-induced Stevens-Johnson syndrome: recurrence after re-challenge with a lower dose. Ann Hematol 2007: 86: 537-538. (Pubitemid 46863894)
46. Nelson RP, Cornetta K, Ward KE, Ramanuja S, Fausel C, Cripe LD,. Desensitization to imatinib in patients with leukemia. Ann Allergy Asthma Immunol 2006: 97: 216-222. (Pubitemid 44272589)
47. Lammie A, Drobnjak M, Gerald W, et al,. Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem 1994: 42: 1417-1425. (Pubitemid 24338014)
48. Liu D, Seiter K, Mathews T, Madahar CJ, Ahmed T,. Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking imatinib mesylate. Leuk Res 2004: 28: S61-S63. (Pubitemid 38251500)
49. Ayirookuzhi SJ, Ma L, Ramshesh P, Mills G,. Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia. Arch Dermatol 2005: 141: 368-370. (Pubitemid 40365453)
50. Kaune KM, Baumgart M, Gesk S, et al,. Bullous Sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib. Arch Dermatol 2008: 144: 361-364. (Pubitemid 351439119)
51. Dib EG, Ifthikharuddin JJ, Scott GA, Partilo SR,. Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy. Leuk Res 2005: 29: 233-234. (Pubitemid 39647519)
52. Breccia M, Carmosino I, Russo E, Morano SG, Latagliata R, Alimena G,. Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. Eur J Haematol 2005: 74: 121-123. (Pubitemid 40175315)
53. Drummond A, Micallef-Eynaud P, Douglas WS, et al,. A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI571, Glivec). Br J Haematol 2003: 120: 911-913. (Pubitemid 36315121)
54. Rousselot P, Larghero J, Raffoux E, et al,. Photosensitization in chronic myelogenous leukemia patients treated with imatinib mesylate. Br J Haematol 2003: 120: 1091-1092. (Pubitemid 36411574)
55. Clark SH, Duvic M, Prieto VG,. Mycosis fungoides-like reaction in a patient treated with Gleevec. J Cutan Pathol 2003: 30: 279-281. (Pubitemid 36555138)
56. Yanagi T, Sawamura D, Shimizu H,. Follicular mucinosis associated with imatinib (STI571). Br J Dermatol 2004: 151: 1276-1278. (Pubitemid 40030183)
57. Bekkenk MW, Vermeer MH, Meijer CJLM, et al,. EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate. Blood 2003: 102: 4243. (Pubitemid 37487014)
58. Breccia M, Latagliata R, Carmosino I, Mandelli F, Alimena G,. Reactivation of porphyria cutanea tarda as a possible side effect of imatinib at high dosage in chronic myeloid leukemia. Leukemia 2004: 18: 182. (Pubitemid 38159461)
59. Ho AYL, Deacon A, Osborne G, Mufti GJ,. Precipitation of porphyria cutanea tarda by imatinib mesylate? Br J Haematol 2003: 121: 375. (Pubitemid 36560607)
60. Ugurel S, Lahaye T, Hildenbrand R, et al,. Panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib. Br J Dermatol 2003: 149: 678-679. (Pubitemid 37281620)
61. Banka N, Aljurf M, Hamadah I,. Imatinib (STI-571)-induced exfoliative dermatitis in a Saudi patient with deck chair sign. Dermatology 2003: 207: 329-330. (Pubitemid 37329210)
62. Hartmann JT, Haap M, Kopp HG, Lipp HP,. Tyrosine kinase inhibitors-a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009: 10: 470-481.
63. Pavlu J, Marin D,. Dasatinib and chronic myeloid leukemia: two-year follow up in eight clinical trials. Clin Lymphoma Myeloma 2009: 9: 417-424.
64. Shah NP, Tran C, Lee FY, et al,. Overriding imatinib resistance with novel ABL kinase inhibitor. Science 2004: 305: 399-401. (Pubitemid 38938156)
65. Kantarjian H, Giles F, Wunderle L, et al,. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006: 354: 2542-2551. (Pubitemid 43882350)
66. Kantarjian HM, Giles F, Gattermann N, et al,. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007: 110: 3540-3546. (Pubitemid 350159618)
67. Talpaz M, Shah NP, Kantarjian H, et al,. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006: 354: 2531-2541. (Pubitemid 43882349)
68. Hochhaus A, Kantarjian HM, Baccarani M, et al,. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007: 109: 2303-2309. (Pubitemid 46425867)
69. Anon. 2006. Results from phase II studies of dasatinib in patients with chronic myeloid leukaemia or Ph+ acute lymphocytic leukaemia with resistance or intolerance to imatinib. 11th Congress of European Hematology. Amsterdam, The Netherlands.
70. Assouline S, Laneuville P, Gambacorti-Passerini C,. Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia. N Engl J Med 2006: 354: 2623-2624. (Pubitemid 43882376)
71. Radaelli F, Bramanti S, Fantini NN, Fabio G, Greco I, Lambertenghi-Deliliers G,. Dasatinib-related alveolar pneumonia responsive to corticosteroids. Leuk Lymphoma 2006: 47: 1180-1181. (Pubitemid 44102990)
72. Sprycel package insert. New York, NY: Bristol-Meyers Squibb. Accessed January 6, 2008.
73. Danielsn CE, Wilkes MC, Edens M, et al,. Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin- mediated lung fibrosis. J Clin Invest 2004: 114: 1308-1316. (Pubitemid 40385302)
74. Akhmetshina A, Dees C, Pileckyte M, et al,. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008: 22: 2214-2222. (Pubitemid 351948641)
75. Distler JH, Distler O,. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis. Rheumatology (Oxford) 2008: 47: v10-v11.
76. Giles FJ,. The toxicities of modern targeted therapies-learning from the price of progress. Target Oncol 2009: 4: 65-66.
77. Roujeau JC, Stern RS,. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994: 331: 1272-1285. (Pubitemid 24333193)